Autoresearch: As of 19 Sep 2026, is there clinical evidence that orexin agonism compresses sleep need and reduces systemic inflammation, and how is Lilly framing Centessa?

Generated by /autoresearch on 2026-09-19 (empirical/clinical gap routed through Consensus abstracts + issuer/CT.gov). Synthesized across 2 rounds. See Provenance. Treat as raw material — review before promoting into a project or thread. Context: vault/projects/stock-market Research-only. No buy/sell/size.

Summary

Step 3 remains unverified as a lifestyle/anti-inflammatory claim. Lilly closed the Centessa deal on 24 Jun 2026 and framed it as “treatments for sleep-wake disorders” / narcolepsy — not a GLP-1-scale franchise and not inflammation (Lilly PR). ORX750 (cleminorexton) has Phase 1 MWT wake-promotion in sleep-deprived volunteers; CRYSTAL-1 (NT1/NT2/IH) is still recruiting with primary completion Dec 2026. Peer-reviewed inflammation work is preclinical, and one 2026 mouse paper finds a dual orexin antagonist (daridorexant) reduces LPS cytokines — the opposite sign of “agonism → less inflamed.” Stay hypothesis. Steps 3–4 stay open.

Findings

Lilly’s own words are sleep-wake, not lifestyle

“Eli Lilly and Company today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders.” Carole Ho: orexin “governing wakefulness, alertness, and the stability of sleep”; “For people living with narcolepsy…”; reach “to diseases impacted by disrupted sleep” (Lilly PR, 24 Jun 2026). That weakens Step 2’s “same playbook / terracorn” intent without killing the acquisition fact (Step 1).

Wake-promotion has a Phase 1 signal; patient pivotal data are not in

Hartman et al. 2025 (SLEEP abstract): ORX750 MWT LS-mean difference vs placebo 8.1 / 15.2 / 20.2 min at 1.0 / 2.5 / 3.5 mg; normative wakefulness (>30 min) at ≥2.5 mg; TEAEs “transient and mild” (0863 Phase 1 Clinical Data with ORX750). Dauvilliers et al. 2025: Phase 2a basket design; “Data for all three disorders are expected in 2025” — but CT.gov NCT06752668 is still RECRUITING, completion 2026-12 (CT.gov CRYSTAL-1). SAPPHIRE (NCT07598708) started 15 May 2026, primary 30 Sep 2027 (CT.gov SAPPHIRE). No listed ORX750 inflammation endpoint.

Inflammation is the wrong sign, the wrong molecule, or not clinical

Horiuchi et al. 2026: daridorexant (antagonist) mitigated LPS-induced hypothalamic cytokines and acute lung inflammation in mice (Orexin Receptor Antagonism… FASEB). Becquet 2019: orexin-A peptide (not an oral OX2R agonist) ameliorated EAE neuroinflammation (Journal of Neuroinflammation). Hakizimana 2026 systematic review: inflammation suppresses orexin; orexin-A is anti-inflammatory mostly in animals; “significant gaps remain in human mechanistic studies” (Clinical and Experimental Neuroimmunology). None is an ORX750 systemic-inflammation readout. “You sleep less but you become less inflamed” remains a podcast sentence.

Contradictions and open questions

• Step 2: Lilly describes a neuroscience bolt-on to sleep-wake, not “own the category before it exists.” Keep partial.
• Step 3: wake-promotion in healthy sleep-deprived volunteers ≠ compressed sleep need in normals, and ≠ less systemic inflammation.
• An antagonist improving inflammation is an active contradiction of the agonism→anti-inflammatory story.
• CRYSTAL-1 / SAPPHIRE readouts are the next catalysts; they are sleep-disorder trials.

Provenance

Rounds run: 2 of 3 (early-exit — issuer framing + CT.gov + Consensus closed the inflammation gap as “not shown”). X sources: attempted via X search_news; spend-cap 403. Not used. Grokipedia: not used. Academic: Consensus MCP, two queries (ORX750 clinical; orexin×inflammation).

Web / paper sources:

• Lilly PR 24 Jun 2026 — issuer — close; sleep-wake framing.
• CT.gov NCT06752668 — official — CRYSTAL-1 recruiting; Dec 2026.
• CT.gov NCT07598708 — official — SAPPHIRE May 2026–2027.
• Hartman 2025 — Phase 1 MWT.
• Horiuchi 2026 — antagonist, not agonist, vs LPS.

Generated: 2026-09-19